世界の静脈内免疫グロブリン療法市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Intravenous Immune Globulin Therapies Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12401 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、静脈内免疫グロブリン療法のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。静脈内免疫グロブリン療法の種類別市場規模（液体、凍結乾燥粉末）、用途別市場規模（免疫不全、自己免疫疾患、急性感染症）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・静脈内免疫グロブリン療法の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Baxter、Grifols、CSL Plasma、Octapharma、Biotest、Kedrion、Kamada、China Biologic Products Holdings、Hualan Biological Engineering、Sichuan Yuanda Shuyang Pharmaceutical ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：液体、凍結乾燥粉末 ・用途別分析2016年-2026年：免疫不全、自己免疫疾患、急性感染症 ・静脈内免疫グロブリン療法の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・静脈内免疫グロブリン療法のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・静脈内免疫グロブリン療法のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・静脈内免疫グロブリン療法の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・静脈内免疫グロブリン療法の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Intravenous Immune Globulin Therapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Intravenous Immune Globulin Therapies size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Intravenous Immune Globulin Therapies market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Intravenous Immune Globulin Therapies market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Liquid Form
Lyophilized Powder Form

Market segment by Application, can be divided into
Immunodeficiency
Autoimmune Disease
Acute Infection

Market segment by players, this report covers
Baxter
Grifols
CSL Plasma
Octapharma
Biotest
Kedrion
Kamada
China Biologic Products Holdings
Hualan Biological Engineering
Sichuan Yuanda Shuyang Pharmaceutical

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Intravenous Immune Globulin Therapies
1.2 Classification of Intravenous Immune Globulin Therapies by Type
1.2.1 Overview: Global Intravenous Immune Globulin Therapies Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Intravenous Immune Globulin Therapies Revenue Market Share by Type in 2020
1.2.3 Liquid Form
1.2.4 Lyophilized Powder Form
1.3 Global Intravenous Immune Globulin Therapies Market by Application
1.3.1 Overview: Global Intravenous Immune Globulin Therapies Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Immunodeficiency
1.3.3 Autoimmune Disease
1.3.4 Acute Infection
1.4 Global Intravenous Immune Globulin Therapies Market Size & Forecast
1.5 Global Intravenous Immune Globulin Therapies Market Size and Forecast by Region
1.5.1 Global Intravenous Immune Globulin Therapies Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Intravenous Immune Globulin Therapies Market Size by Region, (2016-2021)
1.5.3 North America Intravenous Immune Globulin Therapies Market Size and Prospect (2016-2026)
1.5.4 Europe Intravenous Immune Globulin Therapies Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Intravenous Immune Globulin Therapies Market Size and Prospect (2016-2026)
1.5.6 South America Intravenous Immune Globulin Therapies Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Intravenous Immune Globulin Therapies Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Intravenous Immune Globulin Therapies Market Drivers
1.6.2 Intravenous Immune Globulin Therapies Market Restraints
1.6.3 Intravenous Immune Globulin Therapies Trends Analysis
2 Company Profiles
2.1 Baxter
2.1.1 Baxter Details
2.1.2 Baxter Major Business
2.1.3 Baxter Intravenous Immune Globulin Therapies Product and Solutions
2.1.4 Baxter Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Baxter Recent Developments and Future Plans
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business
2.2.3 Grifols Intravenous Immune Globulin Therapies Product and Solutions
2.2.4 Grifols Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Grifols Recent Developments and Future Plans
2.3 CSL Plasma
2.3.1 CSL Plasma Details
2.3.2 CSL Plasma Major Business
2.3.3 CSL Plasma Intravenous Immune Globulin Therapies Product and Solutions
2.3.4 CSL Plasma Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 CSL Plasma Recent Developments and Future Plans
2.4 Octapharma
2.4.1 Octapharma Details
2.4.2 Octapharma Major Business
2.4.3 Octapharma Intravenous Immune Globulin Therapies Product and Solutions
2.4.4 Octapharma Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Octapharma Recent Developments and Future Plans
2.5 Biotest
2.5.1 Biotest Details
2.5.2 Biotest Major Business
2.5.3 Biotest Intravenous Immune Globulin Therapies Product and Solutions
2.5.4 Biotest Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Biotest Recent Developments and Future Plans
2.6 Kedrion
2.6.1 Kedrion Details
2.6.2 Kedrion Major Business
2.6.3 Kedrion Intravenous Immune Globulin Therapies Product and Solutions
2.6.4 Kedrion Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Kedrion Recent Developments and Future Plans
2.7 Kamada
2.7.1 Kamada Details
2.7.2 Kamada Major Business
2.7.3 Kamada Intravenous Immune Globulin Therapies Product and Solutions
2.7.4 Kamada Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Kamada Recent Developments and Future Plans
2.8 China Biologic Products Holdings
2.8.1 China Biologic Products Holdings Details
2.8.2 China Biologic Products Holdings Major Business
2.8.3 China Biologic Products Holdings Intravenous Immune Globulin Therapies Product and Solutions
2.8.4 China Biologic Products Holdings Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 China Biologic Products Holdings Recent Developments and Future Plans
2.9 Hualan Biological Engineering
2.9.1 Hualan Biological Engineering Details
2.9.2 Hualan Biological Engineering Major Business
2.9.3 Hualan Biological Engineering Intravenous Immune Globulin Therapies Product and Solutions
2.9.4 Hualan Biological Engineering Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Hualan Biological Engineering Recent Developments and Future Plans
2.10 Sichuan Yuanda Shuyang Pharmaceutical
2.10.1 Sichuan Yuanda Shuyang Pharmaceutical Details
2.10.2 Sichuan Yuanda Shuyang Pharmaceutical Major Business
2.10.3 Sichuan Yuanda Shuyang Pharmaceutical Intravenous Immune Globulin Therapies Product and Solutions
2.10.4 Sichuan Yuanda Shuyang Pharmaceutical Intravenous Immune Globulin Therapies Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Intravenous Immune Globulin Therapies Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Intravenous Immune Globulin Therapies Players Market Share
3.2.2 Top 10 Intravenous Immune Globulin Therapies Players Market Share
3.2.3 Market Competition Trend
3.3 Intravenous Immune Globulin Therapies Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Intravenous Immune Globulin Therapies Revenue and Market Share by Type (2016-2021)
4.2 Global Intravenous Immune Globulin Therapies Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Intravenous Immune Globulin Therapies Revenue Market Share by Application (2016-2021)
5.2 Intravenous Immune Globulin Therapies Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Intravenous Immune Globulin Therapies Revenue by Type (2016-2026)
6.2 North America Intravenous Immune Globulin Therapies Revenue by Application (2016-2026)
6.3 North America Intravenous Immune Globulin Therapies Market Size by Country
6.3.1 North America Intravenous Immune Globulin Therapies Revenue by Country (2016-2026)
6.3.2 United States Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
6.3.3 Canada Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
6.3.4 Mexico Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Intravenous Immune Globulin Therapies Revenue by Type (2016-2026)
7.2 Europe Intravenous Immune Globulin Therapies Revenue by Application (2016-2026)
7.3 Europe Intravenous Immune Globulin Therapies Market Size by Country
7.3.1 Europe Intravenous Immune Globulin Therapies Revenue by Country (2016-2026)
7.3.2 Germany Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
7.3.3 France Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
7.3.5 Russia Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
7.3.6 Italy Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Type (2016-2026)
8.2 Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Application (2016-2026)
8.3 Asia-Pacific Intravenous Immune Globulin Therapies Market Size by Region
8.3.1 Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Region (2016-2026)
8.3.2 China Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
8.3.3 Japan Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
8.3.4 South Korea Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
8.3.5 India Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
8.3.7 Australia Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Intravenous Immune Globulin Therapies Revenue by Type (2016-2026)
9.2 South America Intravenous Immune Globulin Therapies Revenue by Application (2016-2026)
9.3 South America Intravenous Immune Globulin Therapies Market Size by Country
9.3.1 South America Intravenous Immune Globulin Therapies Revenue by Country (2016-2026)
9.3.2 Brazil Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
9.3.3 Argentina Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Type (2016-2026)
10.2 Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Application (2016-2026)
10.3 Middle East & Africa Intravenous Immune Globulin Therapies Market Size by Country
10.3.1 Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Country (2016-2026)
10.3.2 Turkey Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
10.3.4 UAE Intravenous Immune Globulin Therapies Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Intravenous Immune Globulin Therapies Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Intravenous Immune Globulin Therapies Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Intravenous Immune Globulin Therapies Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Intravenous Immune Globulin Therapies Revenue (USD Million) by Region (2016-2021)
Table 5. Global Intravenous Immune Globulin Therapies Revenue Market Share by Region (2021-2026)
Table 6. Baxter Corporate Information, Head Office, and Major Competitors
Table 7. Baxter Major Business
Table 8. Baxter Intravenous Immune Globulin Therapies Product and Solutions
Table 9. Baxter Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Grifols Corporate Information, Head Office, and Major Competitors
Table 11. Grifols Major Business
Table 12. Grifols Intravenous Immune Globulin Therapies Product and Solutions
Table 13. Grifols Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. CSL Plasma Corporate Information, Head Office, and Major Competitors
Table 15. CSL Plasma Major Business
Table 16. CSL Plasma Intravenous Immune Globulin Therapies Product and Solutions
Table 17. CSL Plasma Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Octapharma Corporate Information, Head Office, and Major Competitors
Table 19. Octapharma Major Business
Table 20. Octapharma Intravenous Immune Globulin Therapies Product and Solutions
Table 21. Octapharma Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Biotest Corporate Information, Head Office, and Major Competitors
Table 23. Biotest Major Business
Table 24. Biotest Intravenous Immune Globulin Therapies Product and Solutions
Table 25. Biotest Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Kedrion Corporate Information, Head Office, and Major Competitors
Table 27. Kedrion Major Business
Table 28. Kedrion Intravenous Immune Globulin Therapies Product and Solutions
Table 29. Kedrion Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Kamada Corporate Information, Head Office, and Major Competitors
Table 31. Kamada Major Business
Table 32. Kamada Intravenous Immune Globulin Therapies Product and Solutions
Table 33. Kamada Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. China Biologic Products Holdings Corporate Information, Head Office, and Major Competitors
Table 35. China Biologic Products Holdings Major Business
Table 36. China Biologic Products Holdings Intravenous Immune Globulin Therapies Product and Solutions
Table 37. China Biologic Products Holdings Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Hualan Biological Engineering Corporate Information, Head Office, and Major Competitors
Table 39. Hualan Biological Engineering Major Business
Table 40. Hualan Biological Engineering Intravenous Immune Globulin Therapies Product and Solutions
Table 41. Hualan Biological Engineering Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Sichuan Yuanda Shuyang Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 43. Sichuan Yuanda Shuyang Pharmaceutical Major Business
Table 44. Sichuan Yuanda Shuyang Pharmaceutical Intravenous Immune Globulin Therapies Product and Solutions
Table 45. Sichuan Yuanda Shuyang Pharmaceutical Intravenous Immune Globulin Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Intravenous Immune Globulin Therapies Revenue (USD Million) by Players (2019-2021)
Table 47. Global Intravenous Immune Globulin Therapies Revenue Share by Players (2019-2021)
Table 48. Breakdown of Intravenous Immune Globulin Therapies by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Intravenous Immune Globulin Therapies Players Head Office, Products and Services Provided
Table 50. Intravenous Immune Globulin Therapies Mergers & Acquisitions in the Past Five Years
Table 51. Intravenous Immune Globulin Therapies New Entrants and Expansion Plans
Table 52. Global Intravenous Immune Globulin Therapies Revenue (USD Million) by Type (2016-2021)
Table 53. Global Intravenous Immune Globulin Therapies Revenue Share by Type (2016-2021)
Table 54. Global Intravenous Immune Globulin Therapies Revenue Forecast by Type (2021-2026)
Table 55. Global Intravenous Immune Globulin Therapies Revenue by Application (2016-2021)
Table 56. Global Intravenous Immune Globulin Therapies Revenue Forecast by Application (2021-2026)
Table 57. North America Intravenous Immune Globulin Therapies Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Intravenous Immune Globulin Therapies Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Intravenous Immune Globulin Therapies Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Intravenous Immune Globulin Therapies Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Intravenous Immune Globulin Therapies Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Intravenous Immune Globulin Therapies Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Intravenous Immune Globulin Therapies Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Intravenous Immune Globulin Therapies Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Intravenous Immune Globulin Therapies Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Intravenous Immune Globulin Therapies Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Intravenous Immune Globulin Therapies Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Intravenous Immune Globulin Therapies Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Intravenous Immune Globulin Therapies Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Intravenous Immune Globulin Therapies Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Intravenous Immune Globulin Therapies Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Intravenous Immune Globulin Therapies Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Intravenous Immune Globulin Therapies Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Intravenous Immune Globulin Therapies Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Intravenous Immune Globulin Therapies Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Intravenous Immune Globulin Therapies Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Intravenous Immune Globulin Therapies Picture
Figure 2. Global Intravenous Immune Globulin Therapies Revenue Market Share by Type in 2020
Figure 3. Liquid Form
Figure 4. Lyophilized Powder Form
Figure 5. Intravenous Immune Globulin Therapies Revenue Market Share by Application in 2020
Figure 6. Immunodeficiency Picture
Figure 7. Autoimmune Disease Picture
Figure 8. Acute Infection Picture
Figure 9. Global Intravenous Immune Globulin Therapies Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Intravenous Immune Globulin Therapies Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Intravenous Immune Globulin Therapies Revenue Market Share by Region (2016-2026)
Figure 12. Global Intravenous Immune Globulin Therapies Revenue Market Share by Region in 2020
Figure 13. North America Intravenous Immune Globulin Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Intravenous Immune Globulin Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Intravenous Immune Globulin Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Intravenous Immune Globulin Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Intravenous Immune Globulin Therapies Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Intravenous Immune Globulin Therapies Market Drivers
Figure 19. Intravenous Immune Globulin Therapies Market Restraints
Figure 20. Intravenous Immune Globulin Therapies Market Trends
Figure 21. Baxter Recent Developments and Future Plans
Figure 22. Grifols Recent Developments and Future Plans
Figure 23. CSL Plasma Recent Developments and Future Plans
Figure 24. Octapharma Recent Developments and Future Plans
Figure 25. Biotest Recent Developments and Future Plans
Figure 26. Kedrion Recent Developments and Future Plans
Figure 27. Kamada Recent Developments and Future Plans
Figure 28. China Biologic Products Holdings Recent Developments and Future Plans
Figure 29. Hualan Biological Engineering Recent Developments and Future Plans
Figure 30. Sichuan Yuanda Shuyang Pharmaceutical Recent Developments and Future Plans
Figure 31. Global Intravenous Immune Globulin Therapies Revenue Share by Players in 2020
Figure 32. Intravenous Immune Globulin Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Intravenous Immune Globulin Therapies Revenue Market Share in 2020
Figure 34. Global Top 10 Players Intravenous Immune Globulin Therapies Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Intravenous Immune Globulin Therapies Revenue Share by Type in 2020
Figure 37. Global Intravenous Immune Globulin Therapies Market Share Forecast by Type (2021-2026)
Figure 38. Global Intravenous Immune Globulin Therapies Revenue Share by Application in 2020
Figure 39. Global Intravenous Immune Globulin Therapies Market Share Forecast by Application (2021-2026)
Figure 40. North America Intravenous Immune Globulin Therapies Sales Market Share by Type (2016-2026)
Figure 41. North America Intravenous Immune Globulin Therapies Sales Market Share by Application (2016-2026)
Figure 42. North America Intravenous Immune Globulin Therapies Revenue Market Share by Country (2016-2026)
Figure 43. United States Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Intravenous Immune Globulin Therapies Sales Market Share by Type (2016-2026)
Figure 47. Europe Intravenous Immune Globulin Therapies Sales Market Share by Application (2016-2026)
Figure 48. Europe Intravenous Immune Globulin Therapies Revenue Market Share by Country (2016-2026)
Figure 49. Germany Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Intravenous Immune Globulin Therapies Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Intravenous Immune Globulin Therapies Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Intravenous Immune Globulin Therapies Revenue Market Share by Region (2016-2026)
Figure 57. China Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Intravenous Immune Globulin Therapies Sales Market Share by Type (2016-2026)
Figure 64. South America Intravenous Immune Globulin Therapies Sales Market Share by Application (2016-2026)
Figure 65. South America Intravenous Immune Globulin Therapies Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Intravenous Immune Globulin Therapies Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Intravenous Immune Globulin Therapies Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Intravenous Immune Globulin Therapies Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Intravenous Immune Globulin Therapies Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source

---